[Molecular toxicological mechanism of the lethal interactions of the new antiviral drug, sorivudine, with 5-fluorouracil prodrugs and genetic deficiency of dihydropyrimidine dehydrogenase].

  title={[Molecular toxicological mechanism of the lethal interactions of the new antiviral drug, sorivudine, with 5-fluorouracil prodrugs and genetic deficiency of dihydropyrimidine dehydrogenase].},
  author={Tadashi Watabe and Kenichiro Ogura and Takahito Nishiyama},
  journal={Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan},
  volume={122 8},
  • T. Watabe, K. Ogura, T. Nishiyama
  • Published 1 August 2002
  • Biology, Chemistry, Medicine
  • Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan
In 1993, there were 18 acute deaths in Japanese patients who had the viral disease herpes zoster and were treated with the new antiviral drug sorivudine (SRV, 1-beta-D-arabinofuranosyl-(E)-5-(2-bromovinyl)uracil). All the dead patients had received a 5-fluorouracil (5-FU) prodrug as anticancer chemotherapy concomitant with SRV administration. Studies on toxicokinetics in rats and on hepatic dihydropyrimidine dehydrogenase (DPD), a rate-limiting enzyme for 5-FU catabolism in rats and humans… 
Physicochemical Properties of Causative Drugs Associated with RenalNephrotoxicity
The information could be useful to consider potential risks of renal problems associated with water-soluble drugs at the time of drug approval and after marketing and to compensate for the lack of information.
Intriguing Antiviral Modified Nucleosides: A Retrospective View into the Future Treatment of COVID-19
  • E. Ami, H. Ohrui
  • Biology, Chemistry
    ACS medicinal chemistry letters
  • 2021
The characteristics of the approved antiviral modified nucleoside drugs are described from an organic chemistry perspective and based on the experiences and findings through the development of the HIV-1 reverse-transcriptase inhibitor “Islatravir”, the practical and approximate guidelines for the drug development of antiviralmodified nucleosides against COVID-19 are provided.
Chemical Metabolism of Xenobiotics by Gut Microbiota.
The data currently available on how the gut microbiota directly modifies drugs, dietary compounds, chemicals, pollutants, pesticides and herbal supplements are reviewed.
Xenobiotics: Interaction with the Intestinal Microflora.
Emerging evidence is summarized that illustrates how xenobiotics can affect the gut microbiome structure, create functional changes to the Gut microbiome, and become biotransformed by the gut microbiota.


[Lethal drug interactions of the new antiviral, sorivudine, with anticancer prodrugs of 5-fluorouracil].
In 1993 eighteen Japanese patients with cancer and herpes zoster, a viral disease, died from interactions of the new oral antiviral drug, sorivudine (SRV:
A possible mechanism of eighteen patient deaths caused by interactions of sorivudine, a new antiviral drug, with oral 5-fluorouracil prodrugs.
A toxicokinetic study was performed using rats to investigate the possible mechanism of 18 acute deaths in Japanese patients with cancer and herpes zoster by interactions of the new oral antiviral
Lethal drug interactions of sorivudine, a new antiviral drug, with oral 5-fluorouracil prodrugs.
Data obtained by in vivo and in vitro studies strongly suggested that (E)-5-(2-bromovinyl)uracil generated from SRV by gut flora was reduced in the presense of NADPH to a reactive form by hepatic dihydropyrimidine dehydrogenase (DPD), a key enzyme determining the tissue 5-FU levels, bound covalently to DPD as a suicide inhibitor, and markedly retarded the catabolism of5-FU.
Clinical Pharmacology of 5-Fluorouracil
Summary5-Fluorouracil, first introduced as a rationally synthesised anticancer agent 30 years ago, continues to be widely used in the management of several common malignancies including cancer of the
Dihydropyrimidine dehydrogenase activity in hepatocellular carcinoma: implication in 5-fluorouracil-based chemotherapy.
  • W. Jiang, Z. Lu, Y. He, R. Diasio
  • Medicine, Biology
    Clinical cancer research : an official journal of the American Association for Cancer Research
  • 1997
DPD activity was determined in 50 pairs of tumor and uninvolved liver specimens in Chinese cancer patients with hepatocellular carcinoma and hepatomas were found to have relatively high DPD activity, providing an explanation for the relative 5-fluorouracil resistance of hepatoma.
[Population study of dihydropyrimidine dehydrogenase in cancer patients].
It appears that total DPD deficiency is a very rare event, and pre-treatment DPD activity cannot be a useful indicator for improving 5-FU dose adaptation strategy, but the identification of partial D PD deficiency could lead to starting the treatment with a markedly reduce 5-fu dose.
Dihydropyrimidine dehydrogenase activity in human peripheral blood mononuclear cells and liver: population characteristics, newly identified deficient patients, and clinical implication in 5-fluorouracil chemotherapy.
A sensitive, accurate, and precise DPD assay and a storage method to stabilize DPD activity are developed, permitting large scale DPD screening in cancer patients and a normal distribution (Gaussian distribution) of human D PD activity from peripheral blood mononuclear cells (PBM-DPD) in a population study.
Dihydropyrimidine dehydrogenase activity in a Korean population.
The findings indicate that the activity of DPD in this study was higher than in reports of research with French and white American populations, and to follow a unimodal distribution.
cDNA cloning and chromosome mapping of human dihydropyrimidine dehydrogenase, an enzyme associated with 5-fluorouracil toxicity and congenital thymine uraciluria.
The pig and human dihydropyrimidine dehydrogenase (DPD) cDNAs were cloned and sequenced and the DPD appears to be derived from at least three distinct domains.